Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus : the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. / Ryom, Lene; Dilling Lundgren, Jens; Reiss, Peter; Kirk, Ole; Law, Matthew; Ross, Mike; Morlat, Phillip; Andreas Fux, Christoph; Fontas, Eric; De Wit, Stephane; D'Arminio Monforte, Antonella; El-Sadr, Wafaa; Phillips, Andrew; Ingrid Hatleberg, Camilla; Sabin, Caroline; Mocroft, Amanda; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group.
I: The Journal of Infectious Diseases, Bind 220, Nr. 10, 2019, s. 1629-1634.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus
T2 - the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
AU - Ryom, Lene
AU - Dilling Lundgren, Jens
AU - Reiss, Peter
AU - Kirk, Ole
AU - Law, Matthew
AU - Ross, Mike
AU - Morlat, Phillip
AU - Andreas Fux, Christoph
AU - Fontas, Eric
AU - De Wit, Stephane
AU - D'Arminio Monforte, Antonella
AU - El-Sadr, Wafaa
AU - Phillips, Andrew
AU - Ingrid Hatleberg, Camilla
AU - Sabin, Caroline
AU - Mocroft, Amanda
AU - Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group
PY - 2019
Y1 - 2019
N2 - BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
AB - BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
U2 - 10.1093/infdis/jiz369
DO - 10.1093/infdis/jiz369
M3 - Journal article
C2 - 31504669
VL - 220
SP - 1629
EP - 1634
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 10
ER -
ID: 237753708